Option Care Health, Inc.
31.22USD
-0.0700 (-0.22%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on OPCH.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.49▲ | $0.48 | 5 | 3 |
| Next quarter | $0.54▲ | $0.54 | 0 | 0 |
| Current year | $1.88▲ | $1.84 | 0 | 0 |
| Next year | $2.08▲ | $2.05 | 1 | 0 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.43 | $0.45 | +0.02 (+5.4%) |
| 2026-03-31 | $0.37 | $0.4 | +0.03 (+8.1%) |
| 2025-12-31 | $0.47 | $0.46 | -0.01 (-1.7%) |
| 2025-09-30 | $0.43 | $0.45 | +0.02 (+4.7%) |
69 ratings from 16 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | Downgraded from Buy | Neutral | $39 $32.05 | Oct 9, 2026 |
| William Blair | Downgraded from Outperform | Market Perform | — | Oct 7, 2026 |
| JP Morgan | Downgraded from Overweight | Neutral | $33 | Oct 7, 2026 |
| Citizens | Downgraded from Market Outperform | Market Perform | — | Oct 7, 2026 |
| Jefferies | Downgraded from Buy | Hold | $28 $32.05 | Oct 7, 2026 |
| Barrington Research | Downgraded from Outperform | Market Perform | — | Oct 7, 2026 |
| Deutsche Bank | Downgraded from Buy | Hold | $26 $24 | Jul 30, 2026 |
| Stephens & Co. | Downgraded from Overweight | Equal-Weight | $30 $24 | Jul 17, 2026 |
| Goldman Sachs | Initiated | Neutral | $22 | Jun 8, 2026 |
| Morgan Stanley | Maintained | Overweight | $485 | May 6, 2026 |
| JP Morgan | Maintained | Overweight | $40 $33 | May 4, 2026 |
| Barrington Research | Maintained | Outperform | $42 $32 | May 1, 2026 |
| UBS | Maintained | Buy | $45 $39 | May 1, 2026 |
| TD Cowen | Maintained | Hold | $37 $23 | May 1, 2026 |
| Barrington Research | Maintained | Outperform | $38 $42 | Jan 16, 2026 |
| Morgan Stanley | Maintained | Overweight | $35 $38 | Jan 13, 2026 |
| Citizens | Reiterated | Market Outperform | $36 $38 | Jan 13, 2026 |
| Stephens & Co. | Initiated | Overweight | $40 | Dec 11, 2025 |
| B of A Securities | Maintained | Buy | $32 $35 | Dec 9, 2025 |
| Deutsche Bank | Maintained | Buy | $31 $36 | Dec 9, 2025 |
| TD Cowen | Maintained | Hold | $30 $27 | Nov 3, 2025 |
| Citizens | Maintained | Market Outperform | $38 $36 | Oct 31, 2025 |
| Barrington Research | Maintained | Outperform | $38 | Oct 31, 2025 |
| Morgan Stanley | Initiated | Overweight | $35 | Oct 17, 2025 |
| TD Cowen | Initiated | Hold | $30 | Oct 2, 2025 |
64 filings from 20 insiders · 0 buy / 0 sell over 6m
Officers and directors of OPCH, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BHATIA PRATEEKOfficer | Grant | 39.8k | — | — | Jul 6, 2026 |
| WRIGHT NORMAN LDirector | Grant | 9.0k | — | — | May 20, 2026 |
| DECKMANN NATASHADirector | Grant | 9.8k | — | $19k | May 20, 2026 |
| BODEM BARBARA WDirector | Grant | 9.0k | — | — | May 20, 2026 |
| PATE R CARTERDirector | Grant | 9.0k | — | — | May 20, 2026 |
| BIERBOWER ELIZABETH DDirector | Grant | 9.0k | — | — | May 20, 2026 |
| KRAEMER HARRY M. JANSEN JR.Director | Grant | 21.1k | — | $269k | May 20, 2026 |
| SULLIVAN TIMOTHY PDirector | Grant | 13.8k | — | $108k | May 20, 2026 |
| BRANDT ERIC KDirector | Grant | 11.6k | — | $59k | May 20, 2026 |
| SMYSER COLLINGeneral Counsel | Other | 812 | — | — | May 19, 2026 |
| SULLIVAN TIMOTHY PDirector | Buy | 24.2k | $20.69 | $500k | May 7, 2026 |
| RADEMACHER JOHN CHARLESChief Executive Officer | Buy | 12.5k | $21.18 | $265k | May 4, 2026 |
| SETHNA MEENALChief Financial Officer | Buy | 16.2k | $20.16 | $327k | May 4, 2026 |
| KRAEMER HARRY M. JANSEN JR.Director | Buy | 36.6k | $21.41 | $784k | May 4, 2026 |
| BAVARO MICHAELOfficer | Sell | 6.0k | $33.00 | $198k | Feb 27, 2026 |
| PATE R CARTERDirector | Sell | 30.3k | $32.05 | $971k | Feb 27, 2026 |
| RADEMACHER JOHN CHARLESChief Executive Officer | Other | 11.1k | — | — | Feb 20, 2026 |
| MAGGIO NICOLEOfficer | Grant | 4.2k | — | — | Feb 18, 2026 |
| ADEWUNMI FEMIOfficer | Grant | 9.6k | — | — | Feb 18, 2026 |
| GRASHOFF CHRISTOPHER LOfficer | Grant | 12.7k | — | — | Feb 18, 2026 |
No analyst notes on OPCH yet.
Members whose judged calls on OPCH have played out most reliably.
No settled calls on OPCH yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice
Analyst Ratings
8 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 0 | 11 | 0 | 0 | Hold3.00 |
| 1 mo ago | 4 | 4 | 5 | 0 | 0 | Buy2.08 |
| 2 mo ago | 4 | 4 | 5 | 0 | 0 | Buy2.08 |
| 3 mo ago | 4 | 4 | 5 | 0 | 0 | Buy2.08 |